Pular para o conteúdo principal
Ranking Invest

RCUS - Arcus Biosciences, Inc.

Segmento: HealthcareArcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.

Análise Ranking Invest

Valuation estimado
-17,13%
-$ 720.96 Mi
Valor de Mercado
$ 3.13 Bi
Desconto (AV)-534.3%
IVR
-0.23A companhia vale -0,23 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-0.38O valuation alternativo equivale a -38% do valor de mercado da companhia.
MLL
-0.38O lucro líquido dos controladores em 16 trimestres equivale a -38% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 464.00 Mi

Dívida Líquida

-$ 49.00 Mi

L4T

-$ 460.00 Mi

MM4T

-453.83%

Indicadores Básicos

ROE

-99.14%

Índices de Previsibilidade

Receita Líquida

F0.59

Lucro

B0.26

Margem

C0.41

Índices de Tendência

Receita Líquida

D1.79

Lucro

F-4.56

Margem

F-4.95

Índices de Endividamento

DIV/PAT

-0.11

DIV/L4T

0.11

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.